Food-Grade Exosome Manufacturing
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
The functional food and nutraceutical market is undergoing a decisive shift from live probiotics toward stable, non-viable postbiotic ingredients—and microbial extracellular vesicles (mEVs) are at the center of this transition. As biologically active nanoparticles naturally secreted by food-grade bacteria, mEVs carry defined payloads of proteins, lipids, and nucleic acids that mediate immunomodulatory, barrier-protective, and microbiome-communicating functions without the cold-chain and viability challenges of live cultures. Creative BioMart Microbe addresses this emerging ingredient category with a food-grade mEV manufacturing platform built specifically for functional food, nutraceutical, medical nutrition, and postbiotic ingredient developers.
Our platform delivers mEV ingredients from GRAS Bacillus subtilis, GRAS lactic acid bacteria, and QPS-listed Bifidobacterium and Lactobacillus strains under protocols designed for food-safety compliance rather than pharmaceutical GMP. The workflow integrates food-safe strain qualification, contaminant-controlled fermentation, simulated gastrointestinal (GI) stability assessment, cell-based bioactivity validation for gut health endpoints, and food-matrix formulation compatibility testing into a single, regulatory-aligned service. Every batch is screened for pathogen absence, heavy metals, allergens, and endotoxins at thresholds appropriate for food ingredients. The resulting documentation package—spanning Certificates of Analysis, safety test reports, GI stability data, and bioactivity summaries—is formatted to support FDA GRAS self-affirmations, EFSA novel food consultations, and international food-ingredient registrations. When your product roadmap calls for upgrading a concept to clinical-grade manufacturing, we support the transition through our compliance pathway from Research-Grade to GMP-Grade without starting from scratch. For project-specific requirements or regulatory consultation, contact us to discuss your food-grade exosome manufacturing needs.
Figure 1. Schematic overview of the food-grade microbial extracellular vesicle manufacturing platform, integrating food-safe strain sourcing and verification, contaminant-controlled production, simulated gastrointestinal stability assessment, bioactivity validation, and food-matrix formulation into a comprehensive quality cycle.
Services
Service Workflow
Our food-grade mEV manufacturing process follows a gated quality framework in which each stage generates documentation that supports the next. From strain safety qualification through finished ingredient delivery, traceability and contaminant control remain continuous priorities.
Integrated Food-Grade Exosome Production Service Modules
Our Food-Grade Exosome Manufacturing platform is organized into two specialized service modules that together span the complete pipeline from food-safe production through functional validation. Each module can be engaged independently for targeted support or combined for an integrated development program.
Food-safe strain qualification, contaminant-controlled fermentation, multi-panel food-safety testing, endotoxin and allergen control, and batch-specific Certificate of Analysis—delivering mEV preparations that are analytically characterized, safety-tested, and ready for food product integration under FDA 21 CFR, EFSA novel food, and Codex frameworks.
View Details
INFOGEST-aligned simulated GI digestion stability assessment, post-digestion cargo integrity analysis, intestinal barrier repair assays, multi-endpoint immunomodulation profiling, and comparative strain and batch benchmarking—providing the quantitative efficacy evidence required for health claim substantiation, product differentiation, and regulatory dossier support.
View Details
Samples
We accept client-provided food-grade microbial strains or can source standard GRAS/QPS strains from public culture collections including ATCC and DSMZ. All strains submitted for production must pass food-safety qualification before entering the manufacturing workflow.
| Sample Type |
Requirements |
Shipping Conditions |
| Client-Provided Food-Grade Strains |
Glycerol stock (≥15% v/v) or lyophilized culture; ≥1 mL; species identification confirmed; GRAS/QPS status documentation preferred where available |
Dry ice or cold pack; overnight shipping |
| Standard GRAS/QPS Reference Strains |
Sourced from ATCC, DSMZ, or other culture collections; lead time 1–2 weeks; full safety documentation included with culture certificate |
N/A (sourced internally) |
| Fermented Food Isolates |
Active culture from validated food fermentation; species identity confirmed by 16S rRNA or MALDI-TOF; ≥1 mL culture volume; food-fermentation history documentation preferred |
Cold pack; express shipping |
Advantages
- Regulatory-Aligned Manufacturing — Production and testing protocols built around food-safety regulations (FDA 21 CFR, EFSA novel food guidance) rather than pharmaceutical GMP, supporting more direct GRAS self-affirmation and novel food consultation pathways.
- Comprehensive Multi-Lot Safety Screening — Every production lot is tested for pathogen absence, heavy metals, allergen residues, and endotoxins at food-appropriate thresholds, with full batch-level traceability from strain to finished ingredient.
- Bioactivity-Anchored Quality — Manufacturing decisions are guided by functional validation data—barrier integrity, anti-inflammatory cytokine profiles, immunomodulation, pathogen exclusion—ensuring ingredient quality is defined by biological performance, not just particle counts.
- Formulation-Ready Ingredient Delivery — Compatibility and stability testing in real food matrices (yogurt, beverages, powders, bars) with sensory and shelf-life data that product developers can use directly in formulation R&D.
- Regulatory Documentation Package — Complete safety dossiers, stability reports, and bioactivity summaries formatted to support FDA GRAS self-affirmations, EFSA novel food consultations, and international food-ingredient registrations.
- Pathway to GMP — When your product advances from food to clinical application, our compliance pathway supports the transition with preserved process knowledge and documentation continuity.
Applications
Functional Foods & Nutraceuticals
Food-grade mEVs serve as defined, stable postbiotic ingredients delivering quantified immunomodulatory and barrier-supportive bioactivity in dietary supplements and fortified foods.
Medical Foods & Special Dietary Purposes
Vesicle ingredients support targeted nutritional management of conditions linked to intestinal barrier dysfunction, chronic inflammation, and post-antibiotic dysbiosis, administered under medical supervision.
Fermented Food Innovation
EVs isolated from traditional fermented foods or optimized starter cultures add scientifically validated bioactive value to next-generation fermented beverages, dairy products, and plant-based ferments.
Infant & Pediatric Nutrition
GRAS probiotic-derived vesicles offer a non-viable, ambient-stable alternative to live probiotics for infant formulas and early-life nutritional products where microbial safety demands are highest.
Case Study
Case Study 1: Probiotic Vesicle Transcytosis Across Intestinal Epithelium
The viability of orally consumed mEV ingredients depends on a fundamental question: can intact vesicles cross the intestinal epithelial barrier to reach immune-competent tissue in the lamina propria? Domínguez Rubio et al. (2020) addressed this directly by tracking CFSE-labeled extracellular vesicles from Bacillus subtilis 168—a widely consumed GRAS probiotic—across polarized Caco-2 cell monolayers in a transwell system. The authors demonstrated that intact B. subtilis EVs (mean diameter 115 ± 27 nm) were actively internalized by intestinal epithelial cells and transported to the basolateral compartment via transcytosis without disrupting tight junction integrity, as confirmed by stable TEER values (1,730 ± 84 Ω·cm² over 240 min). Nanoparticle tracking analysis quantified that approximately 30% of apical EVs reached the basolateral side, with 3D confocal tracking revealing preferential Z-axis (apical-to-basal) movement at 3.8 ± 0.6 μm over the first hour. No cytotoxicity or barrier compromise was observed. For food-grade mEV manufacturing, this study provides direct evidence that GRAS-derived vesicles can survive epithelial transit as intact, functional nanoparticles—validating the core premise of orally delivered postbiotic EV ingredients and informing the GI stability assessment protocols integrated into our production workflow.
Figure 2. Intact Bacillus subtilis 168 EVs are transported across Caco-2 cells in a time-dependent active manner. (Rubio, et al. 2020)
Case Study 2: Food-Grade Bifidobacterium Vesicle Immunomodulation
Mandelbaum et al. (2023) characterized the immunomodulatory profile of extracellular vesicles from the Gram-positive gut symbiont Bifidobacterium longum AO44, a QPS-listed species widely used in probiotic foods. Cryo-transmission electron microscopy confirmed vesicle budding from the bacterial cell wall with a mean diameter of approximately 150 nm. Proteomic profiling revealed a unique cargo enriched in ABC transporters and quorum-sensing proteins, distinct from whole-cell and supernatant proteomes—demonstrating that mEVs carry a defined, non-random subset of bacterial effectors. Functionally, B. longum EVs promoted CD4+ and CD8+ T cell activation and proliferation while selectively inducing anti-inflammatory IL-10 secretion in dendritic cell–T cell co-cultures, without triggering pro-inflammatory IL-17. This selective immune-modulatory profile—activation without inflammation—is precisely the functional phenotype that food and nutraceutical developers seek in postbiotic ingredients targeting gut health and systemic immune balance. For food-grade mEV manufacturing, this study illustrates how QPS-listed probiotic-derived vesicles can be produced, characterized, and validated for defined, reproducible bioactivity that supports structure-function claims.
Figure 3. Cryo-transmission electron microscopy images of Bifidobacterium longum extracellular vesicles budding from the bacterial cell wall, nanoparticle tracking analysis size distributions, and proteomic pathway enrichment analyses. (Mandelbaum, et al. 2023)
FAQs
Q: What distinguishes food-grade mEV manufacturing from research-grade or GMP-grade production?
A: Food-grade mEV manufacturing operates under contaminant-control and safety-testing standards aligned to food regulations rather than pharmaceutical GMP. Research-grade production prioritizes experimental flexibility and rapid turnaround for hypothesis testing; GMP production targets clinical-trial compliance with aseptic processing and full batch release testing. Food-grade fills the middle tier: pathogen-free, heavy-metal-controlled, allergen-monitored, and GI-stability-validated ingredients suitable for human consumption, with documentation supporting GRAS self-affirmation and novel food pathways rather than IND filings.
Q: Which microbial strains are eligible for food-grade mEV production?
A: Our platform prioritizes strains with established FDA GRAS status or EFSA QPS listing, including GRAS Bacillus subtilis, GRAS lactic acid bacteria (Lactobacillus acidophilus, L. rhamnosus, L. plantarum), and QPS-listed Bifidobacterium species (B. longum, B. animalis subsp. lactis). Client-provided strains undergo safety qualification (hemolytic activity, antibiotic resistance, biogenic amine production, species identity confirmation) before entering production. Non-GRAS strains with documented safe food-use history are evaluated case-by-case for self-affirmed GRAS or novel food pathways.
Q: Do food-grade mEVs survive passage through the stomach?
A: Our simulated gastrointestinal stability assessment confirms that many mEV preparations retain structural integrity and bioactive cargo after sequential exposure to gastric pH, pepsin, bile salts, and pancreatin. Survival rates vary by vesicle source, culture conditions, and the presence of protective formulation excipients. Published evidence from GRAS Bacillus subtilis EVs demonstrates that approximately 30% of particles undergo intact transcytosis across intestinal epithelial monolayers without compromising barrier integrity. When GI survival is suboptimal, we evaluate protective strategies including microencapsulation, enteric coating, and matrix embedding tailored to the target product format.
Q: What bioactivity data is provided to support health-related claims?
A: We provide cell-based functional data including intestinal epithelial barrier integrity (TEER, tight junction protein expression), anti-inflammatory cytokine profiles (IL-10, TNF-α, IL-6, IL-1β), immunomodulatory screening (dendritic cell–T cell co-cultures), enteric pathogen competitive exclusion, and antioxidant capacity (reactive oxygen species scavenging). These data support structure-function claims for gut health and immune modulation. For specific disease-related health claims, clinical trials conducted by the client or their regulatory consultants may be required depending on jurisdiction; our bioactivity reports serve as preclinical substantiation for such studies.
Q: How are mEVs incorporated into finished food products?
A: We evaluate mEV compatibility with the client’s target product matrix—liquid (beverages, dairy drinks), semi-solid (yogurt, spreads), or dry (powders, bars, capsules)—through dispersion, pH, water-activity, and accelerated stability testing. Sensory impact (taste, odor, mouthfeel, visual) is assessed to define the usage range where bioactivity is retained without compromising consumer acceptance. Common integration formats include dry-blended powders for capsules or sachets, post-pasteurization addition to dairy products, and microencapsulated dispersions for beverages. We provide recommended usage levels (particles per serving), processing limits (maximum temperature, shear stress), and storage condition guidance.
Q: What regulatory documentation is provided to support market access?
A: Each project delivers a regulatory-ready documentation package including strain safety verification report, batch Certificates of Analysis with contaminant test results, GI stability summary, bioactivity validation report, and formulation compatibility assessment. These documents are formatted to support FDA GRAS self-affirmation notices, EFSA novel food consultation dossiers, Health Canada Novel Food submissions, and food-ingredient registrations in other jurisdictions. For clients requiring additional regulatory support beyond standard documentation, we can recommend regulatory consultants specializing in postbiotic and novel food ingredient approvals.
References:
- Rubio, A. P. D., et al. (2020). Transcytosis of Bacillus subtilis extracellular vesicles through an in vitro intestinal epithelial cell model. Scientific Reports, 10(1), 60077.
- Mandelbaum, N., et al. (2023). Extracellular vesicles of the gram-positive gut symbiont Bifidobacterium longum induce immune-modulatory, anti-inflammatory effects. npj Biofilms and Microbiomes, 9, 30.
Related Services:
